Program
Follicle Stimulating Hormone
Also written as “FSH-GEX™”, “Antioxidants + FSH” and “Follitropin Epsilon”.
Its studies are mostly in Infertility, Female · Infertility · Oligospermia, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Glycotope | 30 open or running | phase 2since Jan 23, 2013 | May 11, 2011 | none ahead |
| IBSA Institut Biochimique | 20 open or running | phase 3since Jun 9, 2006 | Jun 9, 2006 | none ahead |
| Hamad Medical | 11 open or running | phase 4since Sep 29, 2026 | Sep 29, 2026 | Oct 15, 2027phase 4 · NCT07862725 |
Also a collaborator on its studies: Glycotope Biotechnology.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 9, 2006First study: phase 3 study in InfertilityNew to IBSA Institut BiochimiqueIBSA Institut Biochimique · NCT00335725 · 151 enrolled · France, Hungary
- May 11, 2011Glycotope’s first study: phase 1 study in Infertility, FemaleNew to GlycotopeGlycotope · NCT01354886 · 19 enrolled · Netherlands
- Nov 9, 2011Phase 1 study in Infertility, FemaleGlycotope · NCT01477073 · 57 enrolled · Netherlands
- Jan 23, 2013Phase 2 study in InfertilityGlycotope · NCT01794208 · 267 enrolled · Germany, Hungary
- Jan 23, 2013Phase 3 study in Oocyte DonationIBSA Institut Biochimique · NCT01785095 · 41 enrolled · Spain
- Sep 29, 2026Hamad Medical’s first study: phase 4 study in OligospermiaNew to Hamad MedicalHamad Medical · NCT07862725 · 360 planned · Qatar
Ahead
- Oct 15, 2027Primary completion: phase 4 study in OligospermiaHamad Medical · NCT07862725
TargetBeta
“Follicle stimulating hormone receptor agonist”ChEMBL 37, by rule
Other programs on FSHR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| follitropin alfarule | Merck KGaA, Darmstadt, Germany | phase 4 | 26 |
| follitropin deltarule | Ferring Pharmaceuticals | phase 3 | 18 |
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07862725Oligospermia · Qatar | 4 | Not yet recruiting | Hamad Medical | Oct 15, 2027 | 360 |
| NCT01794208Infertility · Germany, Hungary | 2 | Completed | Glycotope | Jul 2013 | 267 |
| NCT01785095Oocyte Donation · Spain | 3 | Completed | IBSA Institut Biochimique | Jul 2014 | 41 |
| NCT01477073Infertility, Female · Netherlands | 1 | Completed | Glycotope | Apr 2012 | 57 |
| NCT01354886Infertility, Female · Netherlands | 1 | Completed | Glycotope | Oct 2011 | 19 |
| NCT00335725Infertility · France, Hungary | 3 | Completed | IBSA Institut Biochimique | Dec 2005 | 151 |
How it is read
Names in the registry
- “FSH-GEX™”, 2 entries
- “Follicle Stimulating Hormone”, 2 entries
- “Antioxidants + FSH”, 1 entry
- “Follitropin Epsilon”, 1 entry
- “FSH (Follicle Stimulating Hormone)”, 1 entry
Conditions, from the studies’ own filings
- Infertility, Female, 2 studies
- Infertility, 2 studies
- Oligospermia, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.